Hantavirus Pulmonary Syndrome (HPS) Market Size, Share, and Industry Analysis, By Drug Type (Antivirals, Vasopressors, and Others), By Route of Administration (Oral, Parenteral, and Inhaled), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, and Online Pharmacies), and Regional Forecast, 2026-2034

The hantavirus pulmonary syndrome (HPS) market is anticipated to experience significant growth in the coming years, driven by the increasing incidence of hantavirus outbreaks in various regions, especially in North America & Latin America. Additionally, high mortality rates of this syndrome drive the demand for effective therapeutics, in turn propelling the market growth. Moreover, advancements in diagnostics also support the market growth.

• For instance, according to the data published by the Centers for Disease Control and Prevention (CDC), during the period from 1993 to 2017, 728 cases of hantavirus pulmonary syndrome (HPS) were diagnosed in the U.S.

Hantavirus pulmonary syndrome (HPS) is a severe, potentially fatal respiratory disease caused by hantaviruses, which are carried by rodents. The primary mode of transmission is through inhalation of virus particles from rodent urine, droppings, or saliva. Early symptoms resemble the flu, but the illness can progress rapidly to severe breathing difficulties and even death.

Hantavirus Pulmonary Syndrome (HPS) Market Driver

Increasing Incidence of Hantavirus Outbreaks Drives Market Growth

The global hantavirus pulmonary syndrome (HPS) market is experiencing significant growth due to the sporadic outbreaks of the disease across the globe. This is due to complex, multifactorial environmental drivers such as changes in precipitation, temperature, and food availability, which influence rodent populations.  Owing to these factors, the number of infected individuals is increasing, highlighting the need for improved environmental monitoring and public awareness as well as the demand for effective treatment options.

• For instance, according to the data published by the European Centre for Disease Prevention and Control in January 2023, 1,647 cases of hantavirus infection were reported by 28 European countries in the year 2020.

Download Free sample to learn more about this report.

According to the data published by the European Centre for Disease Prevention and Control in January 2023, the years 2017 and 2019 witnessed a higher number of hantavirus cases across the region

Hantavirus Pulmonary Syndrome (HPS) Market Restraint

Lack of Approved Therapeutics Hinders Market Growth

Currently, there are no U.S. FDA-approved drugs commercially available in the market. In addition, clinical trials that were conducted to evaluate the efficiency and efficacy of ribavirin and plasma therapy showed limited or inconsistent benefit. This results in more dependency on supportive care, which reduces pharmaceutical market activity.

• For instance, according to an article published Springer Nature in October 2020, clinical trials have indicated that ribavirin is not effective when HPS has progressed to the cardiopulmonary phase.

Hantavirus Pulmonary Syndrome (HPS) Market Opportunity

Development of Effective Treatment to Boost the Market Growth in the Future

The development of effective treatments is considered to be the biggest growth opportunity in the hantavirus pulmonary syndrome (HPS) market. Currently, the market is showing a high unmet need for treatment options due to the lack of approved drugs. Due to this, supportive care such as oxygen therapy, ECMO remains the only standard of care. This offers a lucrative opportunity for the operating players to invest in this market.

Segmentation

Key Insights

The report covers the following key insights:

• Epidemiology of Hantavirus Pulmonary Syndrome (HPS)
• Overview: Preventive Measures for Hantavirus Pulmonary Syndrome, By Key Countries/Regions
• Challenges for the Current Treatment Paradigm
• Pipeline Analysis, By Key Players
• Key Industry Development (Mergers, Acquisitions, and Partnerships

Analysis By Drug Type

By drug type, the market is divided into antivirals, vasopressors, and others.

The antivirals segment held a substantial share of the market in 2024. This growth is attributed to their usage in treating HPS along with other supportive care. Additionally, some antiviral drugs are also being evaluated for efficacy & efficiency.

• For instance, favipiravir, an antiviral, has shown effectiveness in hamster models of HPS and is considered a potential candidate for treatment, especially in suspected exposures or clinical settings.

Analysis By Route of Administration

By route of administration, the market is divided into oral, parenteral, and inhaled.

The oral segment held a considerable share of the market. The segment is growing due to its increasing adoption owing to its advantages, ease of administration, high patient adherence, and others. The majority of the currently used medications are available in oral forms such as tablets, capsules, etc.

• For instance, Ribavirin – one of the antiviral drugs used for severe HPS cases is available in tablet form as well.

Analysis By Distribution Channel

By distribution channel, the market is divided into hospital pharmacies, retail pharmacies & drug stores, and online pharmacies.

The hospital pharmacies segment held a prominent share of the market. The hospitals are the primary centers for the diagnosis and treatment of HPS, which drives the segment's growth. Additionally, hospital pharmacies provide immediate access to medications to ensure timely treatment for the hantavirus infection, which supports the segment growth during the forecast period.

Regional Analysis

Request for Customization   to gain extensive market insights.

By region, the market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America.

North America accounted for a substantial share of the global hantavirus pulmonary syndrome (HPS) market in 2024. High disease burden in the region, strong healthcare infrastructure, and supportive government initiatives to increase public awareness are some of the factors driving the regional growth.

• For instance, according to the data published by the Centers for Disease Control and Prevention (CDC) in June 2024, 864 hantavirus cases were reported in the U.S. as of the end of 2022.

Europe held a considerable share of the hantavirus pulmonary syndrome (HPS) market. The growth of the region is due to several factors, such as government initiatives and a growing number of hantavirus infection cases across the European Union countries. Additionally, European governments are actively involved in raising awareness regarding the infection and its spread.

Asia Pacific is expected to grow substantially in the forthcoming years. This is due to several factors, including growing case identification, increasing government initiatives, rising collaborations for R&D, and others.

Key Players Covered

The global hantavirus pulmonary syndrome (HPS) market is fragmented, with the presence of several players. The report includes the profiles of the following key players:

• Hoffmann-La Roche Ltd (Switzerland)
• Aurobindo Pharma Limited (India)
• Pfizer Inc. (U.S.)
• Viatris Inc. (U.S.)
• Teva Pharmaceutical Industries Ltd (Israel)
• ARS Pharmaceuticals Operations, Inc. (U.S.)
• Sandoz Inc. (Switzerland)

Key Industry Developments

• In July 2024, Arizona public health officials published a warning regarding the spread of a potentially fatal form of hantavirus.
• In January 2022, Atriva Therapeutics GmbH announced that its lead candidate, zapnometinib (ATR-002), received Orphan Drug Designation (ODD) by the U.S. FDA to treat hantavirus infections.